SavedAdd your journal

Journals / Sigma Mühendislik ve Fen Bilimleri Dergisi / 2013 / Cilt: 31 - Sayı: 4

MELANOMA CANCER

Kadriye KIZILBEY
Zeynep MUSTAFAEVA AKDESTE
Pages
555–569
Publication Date
2013-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Early diagnosis of melanoma can be cured completely but it may become dangerous in spread out and advanced state.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Melanoma is a type of skin cancer that begins in cells that produce the pigment on the surface of the skin.
📊
Key Findings & Data:Melanocytes are settled cells on the skin's upper layer that give color to the skin.
💡
Conclusion & Impact:Early diagnosis of melanoma can be cured completely but it may become dangerous in spread out and advanced state.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Melanoma · skin · cancer

Abstract

Melanoma is a type of skin cancer that begins in cells that produce the pigment on the surface of the skin. Melanocytes are settled cells on the skin's upper layer that give color to the skin. Cancer is limitless and dispersed growth of melanocytes cells that give color to skin. Time is needed for the growth of the cells, and they grow into the depths of the skin. Changed very nature melanocytes rapidly spread to other tissues by taking the place of normal tissues or disrupting the function of them. By reaching the blood and lymph vessels it can access to the body and become life-threatening illness. The diagnosis of melanoma is easy if it is still on skin surface. Early diagnosis of melanoma can be cured completely but it may become dangerous in spread out and advanced state.

🔖

Cite This Article

KIZILBEY, K., AKDESTE, Z. M. (2013). MELANOMA CANCER. Sigma Mühendislik ve Fen Bilimleri Dergisi, Cilt: 31 - Sayı: 4, 555–569. https://ajindex.com/articles/419486

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. . What you need to know about cancer, (NIH Publication National Cancer Institute). [2] Blanchard, T., Srivastava, P.K., and Duan, F. (2013). Vaccines against advanced melanoma. Clinics in Dermatology 31, 179-190. [3] Lee, C., Collichio, F., Ollila, D., and Moschos, S. (2013). Historical review of melanoma treatment and outcomes. Clinics in Dermatology 31, 141-147. [4] Rajpar, S., and Marsden, J. (2008).
  2. ABC of skin cancer, Volume 140, (BMJ Books). [5] Health, N.I.o. (1988). In National Cancer Institute. [6] Skin Cancer Foundation. Melanoma Warning Signs and Images. Available from: http://www.skincancer.org/skin-cancer-information/melanoma [Erişim tarihi;01.12.2011]. [7] Kaufman, H.L. (2005). The melanoma book: a complete guide to prevention and treatment, (Gotham). [8] Winslow, T (2008) National Cancer Institute at the National Institutes of Health. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/melanoma/Patient/page2 [Erişim tarihi;10.11.2011]. [9] Özçelik, S., and Akyol, M. (2007). Melanoma Epidemiyolojisi. TURKDERM 41, 5. [10] Kızılbey, K. (2012). Melanoma hastalığını oluşturan sentetik peptidlerin poliakrilikasit ve kopolimerleri ile konjugasyonu. In Biochemistry. (İstanbul: Yildiz Technical University). [11] International Agency for Research on Cancer, World Health Organisation. Available from: http://globocan.iarc.fr/ [Erişim tarihi;03.12.2011]. [12] Clark, J.R., and March, J.B. (2006). Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends in biotechnology 24, 212-218. [13] Gurunathan, S., Klinman, D.M., and Seder, R.A. (2000). DNA vaccines: immunology, application, and optimization*. Annual review of immunology 18, 927-974. [14] Coates, T., Wilson, R., Patrick, G., André, F., and Watson, V. (2001). Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clinical therapeutics 23, 392-403. [15] Moĭsa, A., and Kolesanova, E. (2010). [Synthetic peptide vaccines]. Biomeditsinskaia khimiia 57, 14-30. [16] Magliani, W., Conti, S., Salati, A., Arseni, S., Ravanetti, L., Frazzi, R., and Polonelli, L. (2003). Biotechnological approaches to the production of idiotypic vaccines and antiidiotypic antibiotics. Current Pharmaceutical Biotechnology 4, 91-97. [17] Barrios, Y., Cabrera, R., Yáñez, R., Briz, M., Plaza, A., Forés, R., Fernández, M.-N., and Díaz-Espada, F. (2002). Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. haematologica 87, 4